Literature DB >> 11788093

Rapid detection of the sacsin mutations causing autosomal recessive spastic ataxia of Charlevoix-Saguenay.

J Mercier1, C Prévost, J C Engert, J P Bouchard, J Mathieu, A Richter.   

Abstract

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS; MIM SACS 270550) is frequent in northeastern Québec. Two causal mutations have been identified in the 11.7-kb single exon sacsin gene by sequence-based analyses. Mutation g.6594delT (DeltaT) was reported in 96% of the patients whereas a g.5254C --> T nonsense mutation has been observed only in 2 families. Here we report a reliable and inexpensive method to detect more than 95% of the ARSACS disease alleles from northeastern Québec using allele-specific oligonucleotide (ASO) hybridization. This procedure is being incorporated into the diagnosis of ARSACS, as well as being used for carrier detection in at-risk families from northeastern Québec.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11788093     DOI: 10.1089/10906570152742326

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  4 in total

1.  Two novel homozygous SACS mutations in unrelated patients including the first reported case of paternal UPD as an etiologic cause of ARSACS.

Authors:  Laura Anesi; Paola de Gemmis; Massimo Pandolfo; Uros Hladnik
Journal:  J Mol Neurosci       Date:  2010-09-18       Impact factor: 3.444

2.  Sacsinopathies: sacsin-related ataxia.

Authors:  Yoshihisa Takiyama
Journal:  Cerebellum       Date:  2007-02-28       Impact factor: 3.847

3.  Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Case Report of a Novel Nonsense Mutation in the SACS Gene.

Authors:  Ayush Agarwal; Divyani Garg; Akash Kharat; Abdul Qavi
Journal:  Ann Indian Acad Neurol       Date:  2020-05-09       Impact factor: 1.383

Review 4.  Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability.

Authors:  Mbarka Bchetnia; Luigi Bouchard; Jean Mathieu; Philippe M Campeau; Charles Morin; Diane Brisson; Anne-Marie Laberge; Hélène Vézina; Daniel Gaudet; Catherine Laprise
Journal:  J Med Genet       Date:  2021-04-28       Impact factor: 6.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.